Despite the appreciable success of synthetic nanomaterials for targeted cancer therapy in preclinical studies, technical challenges involving their large-scale, cost-effective production and intrinsic toxicity associated with the materials, as well as their inability to penetrate tumor tissues deeply, limit their clinical translation. Here, we describe biologically derived nanocarriers developed from a bioengineered yeast strain that may overcome such impediments. The budding yeast Saccharomyces cerevisiae was genetically engineered to produce nanosized vacuoles displaying human epidermal growth factor receptor 2 (HER2)-specific affibody for active targeting. These nanosized vacuoles efficiently loaded the anticancer drug doxorubicin (Dox) and were effectively endocytosed by cultured cancer cells. Their cancer-targeting ability, along with their unique endomembrane compositions, significantly enhanced drug penetration in multicellular cultures and improved drug distribution in a tumor xenograft. Furthermore, Dox-loaded vacuoles successfully prevented tumor growth without eliciting any prolonged immune responses. The current study provides a platform technology for generating cancer-specific, tissue-penetrating, safe, and scalable biological nanoparticles for targeted cancer therapy. 
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affibody | bioengineered yeast | cancer therapy | drug delivery | yeast vacuoles R ecent decades have witnessed the emergence of the nanomedicine era in cancer diagnosis and therapy, made possible by the advent of new synthetic nanomaterials suitable for imaging or drug delivery (1, 2) . Such nanomaterial-based drug delivery systems have shown improved therapeutic efficacy with lower unwanted adverse effects compared with conventional chemotherapy, at least in animal models (1) (2) (3) (4) (5) . Despite the appreciable success of cancer nanomedicines in preclinical studies, only a few such agents have entered clinical trials, and fewer still have shown promising therapeutic outcomes and advanced to subsequent trial stages (6) (7) (8) . Among factors likely to hamper the clinical feasibility of synthetic cancer-targeting nanomaterials are technical challenges involving their pilot scale, cost-effective production, and intrinsic cytotoxicity associated with these materials. In addition to these limitations, tumor tissues have formidable physiological barriers, such as a high interstitial pressure and densely entangled ECM. Most synthetic nanomaterials fail to penetrate tumor tissues deeply and localize only in perivascular areas, thereby limiting their therapeutic efficacy (6) (7) (8) . To overcome the limitations associated with synthetic nanomedicines, researchers have recently developed biologically derived, nanosized vesicles as novel drug delivery systems (9) (10) (11) (12) . Minicells and outer membrane vesicles derived from genetically engineered bacteria and mammalian cell-derived exosomes have shown potent antitumor efficacy (10) (11) (12) (13) (14) . Moreover, such biological vectors can be engineered to achieve cancer cell-specific delivery of diverse cargos by introducing cancer-targeting ligands onto their surfaces (10) (11) (12) . However, concerns remain about the immunogenicity of bacteria-derived vehicles. For exosome-based delivery systems, large-scale, cost-effective methods for producing cancer cell-specific exosomes are currently bottlenecks for future clinical applications. Thus, there is a need for a new class of biologically derived drug delivery systems that have an enhanced tissue-penetrating ability and cancer cell specificity, as well as low immunogenicity and facile drug loading, and that can be produced cost-effectively on a large scale.
To this end, we report here the development of a bio-inspired drug delivery system using vacuoles isolated from genetically engineered yeast cells that may fulfill these unmet needs. Budding yeast (Saccharomyces cerevisiae) is nonhazardous and nonpathogenic, and thus has been used in fermentation products for millennia (15) . In addition, its simple genetic and biochemical manipulations, together with the fact that many yeast genes are conserved among higher eukaryotes, including humans, make it an ideal model for various biological studies (15, 16) . Unlike bacteria, its lipid composition is similar to the composition of mammalian cell membranes, potentially increasing fusion efficiency with the plasma membrane or endolysosomes, and thereby facilitating the release of drugs into targeted cells or tissues (17) (18) (19) (20) . Exploiting these features, we genetically engineered S. cerevisiae to express human epidermal growth factor receptor 2 (HER2)-specific affibody on the vacuolar membrane, enabling the targeting of HER2 receptors that are expressed on various cancers (12, 21, 22) . We further loaded the anti-HER2 affibody-expressing vacuoles (Affi HER2 Vacuole) with the chemotherapeutic drug doxorubicin (Dox), which is widely used in treating solid tumors. We then examined the anticancer effects of the drug-carrying, HER2-targeted vacuoles
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(Affi HER2 Vacuole Dox ) and compared their anticancer efficacy with the anticancer efficacy of the free drug (Free Dox ); drug-free vacuoles (Affi HER2 Vacuole); and affibody-free, Dox-carrying vacuoles (Vacuole Dox ) in HER2-overexpressing, in vitro-cultured, cell-based models and an in vivo mouse xenograft model.
The proposed bioengineered yeast vacuole-based platform partly imparts limitations associated with synthetic cancer-targeting nanomaterials and provides inspiration and future directions for designing of an effective anticancer drug delivery system that could be considered in clinical applications to treat various cancers.
Results and Discussion
Preparation and Characterization of Cancer-Targeting Vacuoles. Although WT yeast cells have two to five large vacuoles that are around 1 μm in diameter, their size and number vary depending upon the cell cycle and environmental conditions, reflecting vacuole-associated fission and fusion events (17, 19, 20, 23) . The processes of fission and fusion are tightly regulated by multiple factors, including Rab GTPases that mediate membrane tethering and docking, which are prerequisites for homotypic vacuole fusion (24) (25) (26) (27) (28) (29) . The major Rab GTPase for yeast vacuole fusion is yeast protein transport 7 (YPT7); thus, its deletion results in a large number of fragmented, nanosized vacuoles (25) (26) (27) (30) (31) (32) . To obtain a high yield of nanosized vacuoles, we generated a yeast strain with a YPT7 deletion (YPT7Δ) (Fig. 1A and Fig. S1A ). Additionally, the yeast cells were genetically engineered to express the HER2-specific affibody on the vacuolar membrane for cancer targeting. Such modified YPT7Δ yeast cells contained a large number of fragmented vacuoles with enhanced colloidal stability. To express the Affibody HER2 on the vacuolar membrane, we genetically fused the gene encoding myc-tagged Affibody HER2 to the 5′ end of the PHO8 gene, which encodes vacuolar transmembrane alkaline phosphatase. The Affibody HER2-expressing vacuoles (Affi HER2 Vacuoles) were then purified as described in SI Materials and Methods, Yeast Strains, Plasmid Construction, and Vacuole Isolation. Specific expression of the PHO8-Affibody HER2 chimeric protein in the Affi HER2 Vacuole was shown by Western blot analysis using antibodies against PHO8 and the myc tag (Fig. 1B) . These Affi HER2 Vacuoles were characterized in terms of their size and morphology using electrophoretic light scattering (ELS) and transmission electron microscopy (TEM) (Fig. 1C and Fig. S1 B and C). These analyses of the Affi HER2 Vacuoles revealed a bilayered, circular morphology with a hydrodynamic diameter of ∼200 nm. The HER2 specificity of the Affi HER2 Vacuole was verified by ELISA. The Affi HER2 Vacuole showed an ∼14-fold higher affinity for HER2 compared with the controls (Fig.  1D) . Importantly, after proteinase kinase (PK) treatment, the Affi HER2 Vacuole showed an almost complete loss of HER2 affinity, indicating that the functional form of the Affibody HER2 was exposed on the exterior vacuole surface. Next, by confocal imaging, we showed that the Affi HER2 Vacuoles were specifically bound to HER2 receptors on the cell surface and internalized through receptor-mediated endocytosis (Fig. 1E) . A large proportion of the Affi HER2 Vacuoles were endocytosed by HER2-overexpressing SKOV3 cells, whereas a relatively low nonspecific uptake was evident in HER2-negative MDA-MB-231 cells. Collectively, these results clearly indicate that the Affi HER2 Vacuole can be used for cancer-specific targeting and drug delivery. Because of their subnanometer size, the engineered, drug-carrying vacuoles could rapidly extravasate and accumulate in the periphery of tumor tissue, where, after cancer receptor engagement, they could undergo endocytosis before releasing their payload and producing cytotoxic effects. In addition, with the available rapid protocols for vacuole preparation and methods for large-scale fermentation of yeasts, it is possible to obtain high yields of vacuoles in a cost-effective manner (26, 33) .
Drug Loading, Quantification, and Release Kinetics. We expected that Dox, a membrane-permeable drug, could be loaded into the membrane and lumen of the Affi HER2 Vacuole through physical adsorption because the lipid composition of the vacuoles is relatively similar to the lipid composition of mammalian cell membranes (10, (17) (18) (19) . As shown, the amount of drug loaded in the vacuoles increased by increasing the initial Dox concentration, suggesting that drug loading was mediated by a concentration gradient (Fig. S2A) . Characterization of the size and shape of the ) by ELS and TEM analyses showed that these vesicles retained an intact circular shape ( Fig. S2 B and C) , confirming that the drug loading did not affect the physical properties of the Affi HER2 Vacuole. Next, we investigated drug release from Affi HER2 Vacuole Dox . As shown, less than 10% of the Dox was released during 24 h of incubation at pH 7.4, whereas drug release was accelerated in an acidic (pH 5.1) environment (Fig. S2D) . These results suggest that the vacuole structure becomes destabilized or disrupted in an acidic pH environment, like that in the lysosome of a cell, enabling the rapid release of the payload, but remains intact and relatively stable under physiological conditions, minimizing leaking of the loaded drug into the circulatory system. This drug release profile is crucial for reducing nonspecific cytotoxicity caused by the free drug and for improving the terminal half-life (t 1/2 ) of the drug in vivo by preventing its rapid metabolism or excretion. to share several features in common with tumors studied in vivo (34) (35) (36) . As shown in Fig. 2C, internalization Dox not only showed a relatively higher uptake in the outer proliferating regions but also penetrated much more deeply into the inner parts of the spheroids, possibly reflecting the advantages of the membrane composition and subnanometer size (mostly below 100 nm) of the vacuoles, which could penetrate more upon saturation of the outer region receptors. The greater penetration and distribution of Affi HER2 Vacuole Dox in both the transwell and spheroid cultures compared with Free Dox were dependent upon incubation time. Moreover, growth inhibition and volume control of the cancer cell spheroids after 96 h of treatment were much greater with Affi HER2 Vacuole Dox than with the other controls (Fig. 2D) . These results are in accordance with previous in vitro findings, showing that cellular targeting and enhanced penetration improved the efficacy of Dox (35) . Taken together, these results show that Affi HER2 Vacuole Dox can selectively deliver a drug payload to targeted cancer cells and exert cytotoxic effects. Importantly, Affi HER2 Vacuole alone is not cytotoxic in cells; therefore, the targeted Affi HER2 Vacuole Dox system could be used to safely treat cancers in vivo.
In Vivo Cancer Targeting, Biodistribution, and Antitumor Efficacy.
Researchers have developed a variety of nanocarriers to improve the therapeutic index of drugs, mainly by increasing their efficacy and reducing their toxic side effects. However, curtailing vector-associated toxicity is technically challenging. Therefore, biomaterials that are biocompatible, bioresponsive, and biodegradable could be advantageous over synthetic vectors and continue to be actively developed (8, 9 (Fig. 3A and Fig. S5A) (Fig. S5B) . The pharmacokinetic parameters obtained after fitting the data in a noncompartmental pharmacokinetic model are also given (Fig. S5B) 3C and Fig. S6A ). The percentage of tumor growth inhibition on the last day of the Affi HER2 Vacuole Dox treatment was 77.8%. Next, the harvested tumors were weighed and analyzed to assess the mechanism of cell killing. Consistent with the observed regression of tumor growth, the average weight of the excised tumors was significantly less in the Affi HER2 Vacuole Dox -treated group than in the control groups (Fig. S6B) . Throughout the treatment, the animals in all of the groups appeared normal, showing no overt signs of toxicity and a consistent body weight (Fig. S6C) . Finally, the apoptosis of cells in the tumor tissue was assessed with TUNEL staining. This assay revealed abundant BrdU-FITC-positive apoptotic cells in the tumors excised from the mice treated with Affi HER2 Vacuole Dox (Fig. 3D and Fig. S6D) (Fig. S7A) .
Next, we evaluated vacuole-induced immune responses both in vitro and in vivo. For the in vitro analyses, we stimulated murine macrophage-like RAW 264.7 cells with either form of the vacuole; LPS was used as a positive control. The TNF-α levels in the vacuole-treated cells were indistinguishable from the TNF-α levels in the PBS-treated cells (Fig. S7B) , whereas LPS caused a significant and substantial cytokine response. These results suggest that the vacuoles used herein are very weakly immunogenic and could be well tolerated upon systemic administration. To confirm the in vivo safety of the vacuoles, we investigated whether repeated systemic injection of vacuoles (WT or Affibody HER2 -modified) overstimulated the immune system. Immune responses were recorded in C57BL/6 mice after systemic administration of 100 or 200 μg of vacuoles for 4 consecutive days by measuring the serum levels of TNF-α, IL-6, and IFN-γ with ELISA. Cytokine levels were evaluated at two time points, 2 h and 24 h, to monitor early and delayed immune responses. Both forms of vacuoles slightly increased the serum levels of TNF-α and IL-6 at the early (2-h) time point but had no effect on IFN-γ levels under any condition (Fig. 4) . Importantly, however, cytokine levels returned to baseline by 24 h in all treatment groups. Moreover, there was no significant difference in immune stimulation at the two different concentrations of vacuoles, and neither treatment resulted in body weight loss or lethality. These results suggest that the vacuoles are nontoxic and well tolerated upon systemic administration. Therefore, the vacuoles themselves do not likely contribute to the antitumor effects by overstimulating immune pathways and, as such, are safe for in vivo systemic administration. Although these preliminary results in mice are encouraging, further blood chemistry and safety profile analyses in higher animals will be required. Fig. 4 . Investigation of immune responses upon treatment with Affi HER2 Vacuoles in C57BL/6 mice. The serum levels of cytokines TNF-α, IL-6, and IFN-γ were quantified by ELISA. Analyses were performed at early (2 h) and late (24 h) time points after treatment with PBS or vacuoles (WT or Affi HER2 -modified: 100 μg and 200 μg each) for 4 consecutive days. Each value represents the mean ± SD (n = 5 mice per group) and was analyzed as described in SI Materials and Methods, Serum Cytokine Analysis.
Conclusion
In conclusion, the proposed approach suggests a platform technology for generating cancer-specific, tissue-penetrating, safe, and scalable biological nanoparticles from a nonhazardous yeast strain as a potential targeted cancer therapy. The developed nanocarriers can be generated on a large scale in a cost-effective manner by optimizing the fermentation and purification methods. The results showed significant tumor growth inhibition due to active drug delivery, enhanced biodistribution within tumors, and minimal toxic side effects using Affi HER2 Vacuole Dox , suggesting that bioengineered vacuoles have potential for use as drug delivery carriers in treating cancers. In the future, we plan to investigate the possibility of loading diverse therapeutic agents, including toxins, within vacuoles and testing their fate, both in vitro and in vivo.
Materials and Methods
Detailed methods on the following subjects are available in SI Materials and Methods: yeast strains, plasmid construction, and vacuole isolation; cell culture and spheroid preparation; characterization of the vacuoles; cell binding and uptake assay; characterization of drug-loaded vacuoles; in vitro drug delivery and cytotoxicity; xenograft model, in vivo targeting, biodistribution and pharmacokinetic analysis; in vivo antitumor effects in NIH3T6.7 xenografts; HUVEC cytotoxicity study; RAW 264.7 cell stimulation assay; serum cytokine analysis; and statistical analyses. All animal experiments were done according to established guidelines and with the approval of the KAIST-Institutional Animal Care Committee (KA2013-25).
